Compare ICMB & RVPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ICMB | RVPH |
|---|---|---|
| Founded | 2012 | 2006 |
| Country | United States | United States |
| Employees | N/A | 14 |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 33.5M | 29.2M |
| IPO Year | 2013 | N/A |
| Metric | ICMB | RVPH |
|---|---|---|
| Price | $1.88 | $0.79 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $66.67 |
| AVG Volume (30 Days) | 56.0K | ★ 2.4M |
| Earning Date | 05-12-2026 | 05-14-2026 |
| Dividend Yield | ★ 27.66% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.04 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.75 | N/A |
| P/E Ratio | $47.00 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.60 | $0.17 |
| 52 Week High | $3.28 | $3.11 |
| Indicator | ICMB | RVPH |
|---|---|---|
| Relative Strength Index (RSI) | 27.26 | 44.03 |
| Support Level | N/A | $0.35 |
| Resistance Level | $3.00 | N/A |
| Average True Range (ATR) | 0.18 | 0.25 |
| MACD | -0.03 | -0.18 |
| Stochastic Oscillator | 26.09 | 4.32 |
Investcorp Credit Management BDC Inc is an externally managed, non-diversified closed-end management investment firm that has elected to be regulated as a business development company (BDC). Its investment objective is to maximize total return to stockholders in the form of current income and capital appreciation by investing in debt and related equity of privately held lower middle-market companies. The company principally invests in the debt of middle-market companies, which it defines as those companies that have an enterprise value.
Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease and Parkinson's disease psychosis and its other drug candidate is RP1208.